Memorial Sloan-Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.
Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan-Kettering Institute in 2009.
Memorial Sloan-Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.
Gerstner Sloan-Kettering student research has been recognized with the Grayer Fellowships, the Catell Fellowship, the Olayan Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowship.
Memorial Sloan-Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.
A new Memorial Sloan-Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.
